Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Nutriband Inc (NQ: NTRB )

4.810 -0.130 (-2.63%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 12,446
Open 4.994
Bid (Size) 4.550 (1)
Ask (Size) 5.150 (2)
Prev. Close 4.940
Today's Range 4.744 - 5.040
52wk Range 2.220 - 9.595
Shares Outstanding 6,356,270
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Nutriband Inc. Issued Full Patent from the Chinese National Intellectual Property Administrant for Its "Abuse and Misuse Deterrent Transdermal System" Application
Via ACCESSWIRE
Nutriband Inc Mosquito Repellent Patch Approved by Ministry of Health of Costa Rica
Via ACCESSWIRE

Performance

YTD
+107.86%
+107.86%
1 Month
-19.43%
-19.43%
3 Month
-11.09%
-11.09%
6 Month
-5.69%
-5.69%
1 Year
+90.87%
+90.87%

More News

Read More
Are Pharma Stocks Harmful To Your Financial Health ?
Via Talk Markets
BioMedNewsBreaks — Nutriband Inc. (NASDAQ: NTRB) Schedules Live Investor Webinar, Q&A Session
Via Investor Brand Network
Join Nutriband's Exclusive Live Investor Webinar and Q&A Session on October 17
Via ACCESSWIRE
BioMedNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Announces Receipt of Notice of Allowance for China Patent Application Covering AVERSA(TM) Technology
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
NTRB Stock Earnings: Nutriband Reported Results for Q1 2024
Via InvestorPlace
As Fentanyl Crisis Escalates, Abuse-Deterrent Formulations to Zero in on the Rising Epidemic of Opiate Abuse
Via FinancialNewsMedia
Exposures Product Safety
As Fentanyl Crisis Escalates, Abuse-Deterrent Formulations to Zero in on the Rising Epidemic of Opiate Abuse
From FN Media Group LLC
Via GlobeNewswire
NUTRIBAND RECEIVES CHINA PATENT NOTICE OF ALLOWANCE FOR ITS AVERSA™ ABUSE DETERRENT TRANSDERMAL TECHNOLOGY
Via FinancialNewsMedia
Topics Intellectual Property
Exposures Intellectual Property
Nutriband Receives China Patent Notice of Allowance for Its Aversa(TM) Abuse Deterrent Transdermal Technology
Via ACCESSWIRE
BioMedNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Inks Licensing Agreement to Use Bitrex(R) Aversive Agent for Flagship Product
Via Investor Brand Network
Women Reach Settlement After Yale Nurse Switched Painkillers with Saline Solution
Via Investor Brand Network
Topics Lawsuit
Exposures Financial Legal
Nutriband Licenses Bitrex(R) Brand Aversive Agent for Its Lead Product - Aversa(TM) Fentanyl Transdermal Patch
Via ACCESSWIRE
BioMedNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Reports on Share Repurchase Program
Via Investor Brand Network
Microsoft, Intel And 3 Stocks To Watch Heading Into Tuesday
Via Benzinga
Nutriband Inc. Authorizes $1M Share Buyback Program
Via ACCESSWIRE
BioMedNewsBreaks — Nutriband Inc. (NASDAQ: NTRB) Releases Q2 Report, AVERSA Fentanyl Update
Via Investor Brand Network
Exposures Product Safety
Nutriband Inc. Quarterly Report Highlights Strong Cash Position, and Strategic Progress Toward NDA Filing for AVERSA Fentanyl in 2025
Via ACCESSWIRE
Proposed US Law Would Direct Opioid Settlement Cash to Opioid Crisis Management
Via Investor Brand Network
BioMedNewsBreaks — Nutriband Inc. (NASDAQ: NTRB) Execs to Participate in July 25 Investor Webinar
Via Investor Brand Network
Join Nutriband's Exclusive Live Investor Webinar and Q&A Session on July 25
Via ACCESSWIRE
BioMedNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Obtains Notice of Allowance for Key Trademark Identified as ‘Integral’ to Platform Technology
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Nutriband Receives Notice of Allowance for U.S. Trademark Covering AVERSA(TM) Abuse Deterrent Technology
Via ACCESSWIRE
BioMedNewsBreaks — Nutriband Inc. (NASDAQ: NTRB) Shares Update on Its AVERSA(TM) Fentanyl Product Development Program
Via Investor Brand Network
Exposures Product Safety
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.